Enanta Pharmaceuticals, Inc.

NASDAQ
ENTA
Stock
Yield per half year: -34.2%
Dividend yield: 0%
Sector: Healthcare

Share chart Enanta Pharmaceuticals, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc., биотехнологическая компания, открывает и разрабатывает низкомолекулярные препараты для лечения вирусных инфекций и заболеваний печени. Его цели исследований и разработок включают респираторно-синцитиальный вирус, SARS-CoV-2, метапневмовирус человека и вирус гепатита B. Компания имеет совместную разработку и лицензионное соглашение с Abbott Laboratories для выявления, разработки и коммерциализации соединений ингибиторов протеазы NS3 и NS3/4A HCV, включая паритапревир и глекапревир для лечения хронического вируса гепатита С. Enanta Pharmaceuticals, Inc.

more details
была основана в 1995 году и имеет штаб-квартиру в Уотертауне, штат Массачусетс.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Main settings

IPO date 2013-03-21
ISIN US29251M1062
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Сайт link
Цена ао 5.81
Change price per day: 0% (5.81)
Change price per week: -4.28% (6.07)
Change price per month: +4.12% (5.58)
Change price per 3 month: -31.57% (8.49)
Change price per half year: -34.2% (8.83)
Change price per year: -51.3% (11.93)
Change price per 3 year: -85.28% (39.47)
Change price per 5 year: -88.71% (51.48)
Change price per 10 year: -83.03% (34.23)
Change price per year to date: -4.75% (6.1)
All parameters

Grade

Underestimation
Title Value Grade
P/S 3.41 5
P/BV 1.79 8
P/E 436.7 1
EV/EBITDA -2.38 0
Total: 5.5
Efficiency
Title Value Grade
ROA, % -27.67 0
ROE, % -67.17 0
Total: 0
Dividends
Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0.1371
Debt
Title Value Grade
Debt/EBITDA -0.5307 10
Total: 9.4
Growth impulse
Title Value Grade
Yield Revenue, % -44.78 0
Yield Ebitda, % 319.66 10
Yield EPS, % 202.39 10
Total: 6
More

Insider trading

Main owners

Institutions Volume Share, %
Armistice Capital, LLC 2 064 000 9.76
Farallon Capital Management Llc 2 025 000 9.57
Blackrock Inc. 1 934 711 9.14
Vanguard Group Inc 1 793 786 8.48
Morgan Stanley 1 173 058 5.54
Northern Trust Corporation 935 493 4.42
Acadian Asset Management. LLC 842 944 3.98
Millennium Management LLC 765 141 3.62
Krensavage Asset Management, LLC 742 824 3.51
Shaw D.E. & Co., Inc. 638 168 3.02

Similar companies

P/E & P/BVEV/Ebitda & Debt/Ebitda


Company management

Head Job title Payment Year of birth
Mr. Paul J. Mellett Jr. Chief Financial & Administrative Officer 666.84k 1955 (70 years)
Dr. Yat Sun Or Ph.D. Senior VP of Research & Development and Chief Scientific Officer 729.31k 1952 (73 years)
Ms. Tara Lynn Kieffer Ph.D. Chief Product Strategy Officer 496.85k 1978 (47 years)
Mr. Brendan Luu Chief Business Officer 622.86k 1975 (50 years)
Ms. Jennifer Viera Senior Director of Investor Relations & Corporate Communications N/A
Mr. Nathaniel S. Gardiner J.D. Consultant 672.67k 1954 (71 year)
Dr. Jay R. Luly Ph.D. President, CEO & Director 1.25M 1956 (69 years)
Dr. Scott T. Rottinghaus M.D. Senior VP & Chief Medical Officer 616.73k 1974 (51 year)
Mr. Matthew P. Kowalsky J.D. Chief Legal Officer 1973 (52 years)

About company

Address: United States, Watertown. MA, 500 Arsenal Street - Open in google maps, Open in yandex maps
Website: https://www.enanta.com